Short Communication Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.4.059

MEK Inhibition in KRAS Mutated NSCLC: Quo vadis?

  • 1Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland
  • 2Department of Life Technologies, University of Turku, FI-20520 Turku, Finland
  • 3Department of Medical Oncology/Hematology, Cantonal Hospital Graubu?nden, Loëstrasse 170, 7000 Chur, Switzerland
  • 4Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Petersgraben 4, 4031 Basel,Switzerland
  • 5Department of Medical Oncology, University of Berne, Bern, Switzerland
+ Affiliations - Affiliations

Corresponding Author

Kira-Lee Koster, Kira-Lee.Koster@kssg.ch

Received Date: December 21, 2021

Accepted Date: January 12, 2022

Author Information X